Adaptive Biotechnologies (ADPT) Stock Price
Adaptive Biotechnologies Price
Revenue has compounded at 27.3% per year over the past 8 years to 265.20 M USD. Adaptive Biotechnologies's net margin stands at -22.4%, up from -134.3% several years earlier. Analysts set a median price target of 25.00 USD, implying 2.4% below the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus.
Adaptive Biotechnologies stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Adaptive Biotechnologies business model & stock analysis
Frequently asked questions about Adaptive Biotechnologies
The business model of Adaptive Biotechnologies Corp revolves around leveraging their proprietary immune medicine platform to develop and commercialize innovative diagnostic tests and therapeutics for various diseases. By using high-throughput sequencing to study the adaptive immune system, the company aims to understand and decode the high complexity of immune responses. This enables them to identify and analyze the biomarkers related to various diseases, including cancer and infectious diseases, resulting in the development of targeted diagnostic tools and potential treatment options. With their focus on precision medicine, Adaptive Biotechnologies Corp aims to improve patient outcomes and contribute to the advancement of personalized healthcare.
Adaptive Biotechnologies Corp is primarily active in the biotechnology industry.
Adaptive Biotechnologies Corp faces competition from various companies in the market. Some notable competitors include Pacific Biosciences of California Inc., Illumina Inc., Guardant Health Inc., and QIAGEN N.V. These companies also operate in the field of biotechnology, focusing on next-generation sequencing technologies and providing molecular diagnostic solutions. However, Adaptive Biotechnologies Corp distinguishes itself through its innovative and proprietary immune medicine platform, enabling the study of immune systems. By leveraging its unique technology, Adaptive Biotechnologies Corp maintains a competitive edge in the market.
Adaptive Biotechnologies Corp is a healthcare company specializing in decoding the adaptive immune system to improve patient care. Founded in 2009 by Chad Robins and Harlan Robins, the company's innovative approach focuses on combining high-throughput sequencing with advanced bioinformatics to study the immune system and enable discoveries in various disease areas. Adaptive Bio has collaborations with leading pharmaceutical companies and research institutions worldwide. With its deep understanding of the adaptive immune system, the company aims to develop revolutionary diagnostics and therapies for diseases like cancer, autoimmune disorders, and infectious diseases. Adaptive Biotechnologies Corp is committed to transforming medicine through its cutting-edge technologies and unique insights into the immune system.
Some significant milestones achieved by Adaptive Biotechnologies Corp include the successful completion of their initial public offering (IPO) in June 2019, raising approximately $345 million. They have also entered into collaborations and partnerships with notable organizations, such as Genentech, Microsoft, and Amgen, among others. Adaptive Biotechnologies Corp has made significant advancements in deciphering the adaptive immune system with their proprietary immune medicine platform. This has led to the development of groundbreaking diagnostic tools and therapeutics for various diseases, including cancer. They continue to expand their reach globally and are committed to advancing precision medicine through their innovative approach to harnessing the power of the immune system.
Adaptive Biotechnologies Corp is primarily present in the United States.
Adaptive Biotechnologies Corp represents a strong commitment to revolutionizing the diagnosis and treatment of diseases through its innovative biotechnology solutions. The company's corporate philosophy revolves around harnessing the power of the adaptive immune system to develop precise and accurate diagnostic tests and personalized therapeutics for various diseases. Adaptive Biotechnologies Corp strives to improve patient outcomes by combining cutting-edge technology, computational biology, and extensive research expertise. With an unwavering focus on advancing precision medicine, Adaptive Biotechnologies Corp aims to empower healthcare professionals with the tools they need to make informed decisions and improve the lives of patients.
Analysts currently set an average price target of 24.38 USD for the Adaptive Biotechnologies stock (median: 25.00 USD), implying -4.8 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Adaptive Biotechnologies stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Adaptive Biotechnologies to generate revenue of 293.44 M USD and earnings per share of -0.55 USD.
Converted at the current exchange rate, the Adaptive Biotechnologies share trades at 22.84 EUR (25.62 USD).
The Adaptive Biotechnologies share (ADPT) is listed on 5 stock exchanges, including: NASDAQ (ADPT), XETRA (1HM.DE), Frankfurt (1HM.F), München (1HM.MU), Düsseldorf (1HM.DU).
Adaptive Biotechnologies Corp is a biomedical company that focuses on the development of diagnostic tests and therapies to combat cancer and infectious diseases. The company was founded in 2009 and is headquartered in Seattle, Washington.
The expected revenue of Adaptive Biotechnologies is 293.44 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Adaptive Biotechnologies is -83.55 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Adaptive Biotechnologies is currently -46.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adaptive Biotechnologies stock.
The price-to-sales ratio (P/S) of Adaptive Biotechnologies is currently 13.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Adaptive Biotechnologies stock.
The Eulerpool Quality Score for Adaptive Biotechnologies is 3/10.
The ISIN of Adaptive Biotechnologies is US00650F1093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Adaptive Biotechnologies is A2PLR5. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Adaptive Biotechnologies is ADPT. The ticker symbol is used to trade Adaptive Biotechnologies shares on the stock exchange.
Adaptive Biotechnologies stock
Adaptive Biotechnologies Peer Group
Adaptive Biotechnologies Ticker
Adaptive Biotechnologies FIGI
All fundamentals and in-depth analysis of Adaptive Biotechnologies
Our stock analysis for Adaptive Biotechnologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptive Biotechnologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.